Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives $15.00 Average Price Target from Analysts

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has earned an average rating of “Moderate Buy” from the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, four have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $15.00.

EPRX has been the subject of a number of research analyst reports. William Blair initiated coverage on Eupraxia Pharmaceuticals in a report on Monday, March 23rd. They set an “outperform” rating for the company. Zacks Research cut Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, January 22nd. HC Wainwright lowered their target price on Eupraxia Pharmaceuticals from $12.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. Finally, Lifesci Capital raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 11th.

Eupraxia Pharmaceuticals Stock Performance

NASDAQ:EPRX opened at $7.10 on Tuesday. The stock has a market capitalization of $436.65 million, a P/E ratio of -6.89 and a beta of 1.55. The company has a 50 day moving average price of $7.89 and a 200 day moving average price of $7.04. Eupraxia Pharmaceuticals has a fifty-two week low of $2.68 and a fifty-two week high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its earnings results on Thursday, March 19th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.21). Research analysts forecast that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EPRX. Royal Bank of Canada boosted its position in Eupraxia Pharmaceuticals by 21.1% in the 1st quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock valued at $1,125,000 after buying an additional 59,683 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Eupraxia Pharmaceuticals by 593.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after buying an additional 16,017 shares during the period. Quadrature Capital Ltd purchased a new position in shares of Eupraxia Pharmaceuticals in the 2nd quarter valued at about $61,000. Bank of America Corp DE boosted its stake in shares of Eupraxia Pharmaceuticals by 402.4% in the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after buying an additional 10,059 shares during the period. Finally, TCI Wealth Advisors Inc. purchased a new position in shares of Eupraxia Pharmaceuticals in the 3rd quarter valued at about $65,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.